Armbruster Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,387
| Closed | -$205K | – | 127 |
|
|
2026
Q1 | $205K | Buy |
+3,387
| New | +$197K | 0.03% | 130 |
|
|
2023
Q4 | – | Sell |
-3,674
| Closed | -$213K | – | 102 |
|
|
2023
Q3 | $213K | Buy |
3,674
+159
| +5% | +$9.74K | 0.05% | 98 |
|
|
2023
Q2 | $225K | Hold |
3,515
| – | – | 0.06% | 98 |
|
|
2023
Q1 | $244K | Hold |
3,515
| – | – | 0.06% | 96 |
|
|
2022
Q4 | $253K | Hold |
3,515
| – | – | 0.07% | 94 |
|
|
2022
Q3 | $250K | Hold |
3,515
| – | – | 0.07% | 95 |
|
|
2022
Q2 | $271K | Hold |
3,515
| – | – | 0.07% | 98 |
|
|
2022
Q1 | $257K | Sell |
3,515
-100
| -3% | -$6.71K | 0.06% | 110 |
|
|
2021
Q4 | $225K | Buy |
3,615
+100
| +3% | +$5.87K | 0.05% | 117 |
|
|
2021
Q3 | $208K | Hold |
3,515
| – | – | 0.06% | 90 |
|
|
2021
Q2 | $235K | Hold |
3,515
| – | – | 0.07% | 90 |
|
|
2021
Q1 | $222K | Hold |
3,515
| – | – | 0.07% | 88 |
|
|
2020
Q4 | $218K | Hold |
3,515
| – | – | 0.07% | 85 |
|
|
2020
Q3 | $212K | Sell |
3,515
-25
| -0.7% | -$1.5K | 0.08% | 84 |
|
|
2020
Q2 | $208K | Buy |
+3,540
| New | +$212K | 0.08% | 83 |
|
|
2020
Q1 | – | Sell |
-3,326
| Closed | -$213K | – | 77 |
|
|
2019
Q4 | $213K | Buy |
+3,326
| New | +$190K | 0.08% | 76 |
|
|
2019
Q1 | – | Sell |
-4,131
| Closed | -$215K | – | 71 |
|
|
2018
Q4 | $215K | Sell |
4,131
-202
| -5% | -$10.9K | 0.11% | 65 |
|
|
2018
Q3 | $269K | Buy |
4,333
+202
| +5% | +$12K | 0.12% | 64 |
|
|
2018
Q2 | $229K | Hold |
4,131
| – | – | 0.11% | 63 |
|
|
2018
Q1 | $261K | Sell |
4,131
-40
| -1% | -$2.57K | 0.12% | 58 |
|
|
2017
Q4 | $256K | Sell |
4,171
-70
| -2% | -$4.38K | 0.12% | 56 |
|
|
2017
Q3 | $270K | Buy |
4,241
+286
| +7% | +$16.7K | 0.14% | 49 |
|
|
2017
Q2 | $220K | Sell |
3,955
-588
| -13% | -$32K | 0.12% | 60 |
|
|
2017
Q1 | $247K | Sell |
4,543
-500
| -10% | -$27.4K | 0.14% | 50 |
|
|
2016
Q4 | $295K | Hold |
5,043
| – | – | 0.17% | 48 |
|
|
2016
Q3 | $272K | Hold |
5,043
| – | – | 0.17% | 50 |
|
|
2016
Q2 | $371K | Hold |
5,043
| – | – | 0.24% | 43 |
|
|
2016
Q1 | $322K | Sell |
5,043
-200
| -4% | -$12.6K | 0.22% | 47 |
|
|
2015
Q4 | $361K | Buy |
+5,243
| New | +$346K | 0.32% | 41 |
|
Other funds holding BMY
Armbruster Capital Management's BMY Position: Q2 2026 in Review
Armbruster Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 3,387 shares — an estimated $205K sold.
Armbruster Capital Management first reported a position in BMY in Q4 2015 and held it in 29 quarters. The position peaked at $371K in Q2 2016. 2,516 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Armbruster Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
- Armbruster Capital Management sold 3,387 Bristol-Myers Squibb shares in Q2 2026, an estimated $205K.
- Armbruster Capital Management first reported a position in Bristol-Myers Squibb in Q4 2015 and held it in 29 quarters.
- Armbruster Capital Management's Bristol-Myers Squibb position peaked at $371K in Q2 2016.
- 2,516 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Armbruster Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.